However, direct comparison trials between S-TKIs, T-TKIs, and combination regimens involving TKIs are still lacking, and therefore, there are still unresolved questions around which is the optimal first-line treatment for patients with advanced EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.